Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (7)

Advertisement

Free access | 10.1172/JCI109792

Thyrotropin-releasing Hormone Stimulation of Adrenocorticotropin Production by Mouse Pituitary Tumor Cells in Culture: POSSIBLE MODEL FOR ANOMALOUS RELEASE OF ADRENOCORTICOTROPIN BY THYROTROPIN-RELEASING HORMONE IN SOME PATIENTS WITH CUSHING'S DISEASE AND NELSON'S SYNDROME

Marvin C. Gershengorn, Carlos O. Arevalo, Elizabeth Geras, and Mario J. Rebecchi

Division of Endocrinology, Department of Medicine, New York University Medical Center, New York 10016

Find articles by Gershengorn, M. in: PubMed | Google Scholar

Division of Endocrinology, Department of Medicine, New York University Medical Center, New York 10016

Find articles by Arevalo, C. in: PubMed | Google Scholar

Division of Endocrinology, Department of Medicine, New York University Medical Center, New York 10016

Find articles by Geras, E. in: PubMed | Google Scholar

Division of Endocrinology, Department of Medicine, New York University Medical Center, New York 10016

Find articles by Rebecchi, M. in: PubMed | Google Scholar

Published June 1, 1980 - More info

Published in Volume 65, Issue 6 on June 1, 1980
J Clin Invest. 1980;65(6):1294–1300. https://doi.org/10.1172/JCI109792.
© 1980 The American Society for Clinical Investigation
Published June 1, 1980 - Version history
View PDF
Abstract

ACTH-producing mouse pituitary tumor cells in culture (AtT-20/NYU-1 cells) were found to have binding sites for thyrotropin-releasing hormone (TRH). These putative receptors bound TRH with high affinity; the apparent equilibrium dissociation constant was 3.7 nM. The affinity of the receptors for a series of TRH analogues was similar to those previously reported for TRH-receptor interactions on thyrotropic and mammotropic cells in culture. Like some human pituitary tumors in situ, AtT-20/NYU-1 cells were found to produce the alpha subunit of the glycoprotein hormones (alpha). Alpha accumulation in the medium was constant (3.1 ng/mg cell protein per h) and was not affected by TRH. In contrast, TRH increased the amount of ACTH accumulated in the medium from AtT-20/NYU-1 cells to 190 and 420% of control at 1 and 24 h, respectively. TRH induced a dose-dependent increase in ACTH release during a 30-min incubation; half-maximal stimulation occurred at ∼0.1 nM. TRH had no effect on ACTH release in vitro from anterior pituitary cells derived from normal rats. Because TRH stimulates release of ACTH in some untreated patients with Cushing's disease and Nelson's syndrome as well as pathological states associated with pituitary tumors (but not in normal subjects), AtT-20/NYU-1 cells may serve as an important in vitro model for human pituitary ACTH-secreting adenomas. Moreover, these findings suggest that the primary abnormality in Cushing's disease and Nelson's syndrome, allowing TRH stimulation of ACTH release, may be intrinsic to neoplastic adrenocorticotrophs rather than in neuroregulation of ACTH release.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1294
page 1294
icon of scanned page 1295
page 1295
icon of scanned page 1296
page 1296
icon of scanned page 1297
page 1297
icon of scanned page 1298
page 1298
icon of scanned page 1299
page 1299
icon of scanned page 1300
page 1300
Version history
  • Version 1 (June 1, 1980): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (7)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts